New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 423-436

  Gerotziafas, Grigoris T ^a,b   Mahé, Isabelle ^c   Elalamy, Ismail ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL LOUIS MOURIER   (France)

Author keywords

Antithrombotic treatment; Apixaban; Dabigatran; Rivaroxaban

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CITALOPRAM; DABIGATRAN; DAPOXETINE; DILTIAZEM; ENOXAPARIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FONDAPARINUX; HEPARIN; INDALPINE; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PAROXETINE; PLACEBO; POSACONAZOLE; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; SERTRALINE; UNINDEXED DRUG; VORICONAZOLE; ZIMELDINE;

ANTICOAGULATION; BLEEDING; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; HOSPITAL PATIENT; HUMAN; INCIDENCE; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84902805507     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S49063     Document Type: Review

References (41)

1. Trousseau A. Phlegmasia alba dolens. In: Trousseau A, editor. [Clinique Medicale de l'Hotel Dieu de Paris]. Paris: Balllier; 1865: 654-712.
2. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007;62(2):126-136.
3. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2000;160(6):761-768.
4. Blom J W, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722.
5. Shen VS, Pollak E W. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justifed? South Med J. 1980;73(7):841-843.
6. White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005;165(15):1782-1787.
7. Polite BN, Lamont EB. Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare benefciaries. Cancer. 2006;106(4):923-930.
8. Rance A, Emmerich J, Guedj C, Fiessinger JN. Occult cancer in patients with bilateral deep-vein thrombosis. Lancet. 1997;350(9089): 1448-1449.
9. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis and treatment. Am J Hematol. 2003;72(1):43-52.
10. Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res. 2003;110(4):167-172.
11. Monreal M, Munoz FJ, Rosa V, et al. Upper extremity DVT in oncological patients: analysis of risk factors. Data from the RIETE registry. Exp Oncol. 2006;28(3):245-247.
12. Coleman R, MacCallum P. Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer. 2010;102 Suppl 1: S17-S23.
13. Kahn SR, Lim W, Dunn AS, et al. American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e195S-e226S.
14. Kearon C, Akl EA, Comerota AJ, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e419S-e494S.
15. Gerotziafas GT, Papageorgiou C, Hatmi M, Samama MM, Elalamy I. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb. 2008;36(3-4): 204-211.
16. Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefts of anticoagulants. Hematology Am Soc Hematol Educ Program. 2010;144-149.
17. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137(12):955-960.
18. Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I22-I30.
19. Gerotziafas GT, Samama MM. Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des. 2005;11(30):3855-3876.
20. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis. 2011;5(1): 33-59.
21. Lassen MR, Laux V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag. 2008;4(6):1373-1386.
22. Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis. 2010;29(1):92-104.
23. Denas G, Pengo V. Emerging anticoagulants. Expert Opin Emerg Drugs. 2011;16(1):31-44.
24. Ufer M. Comparative effcacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010;103(3):572-585.
25. Cohen A; Investigators of the MAGELLAN trial. Rivaroxaban compared with enoxaparin for the prevention of venous thromboem-bolism in acutely ill medical patients. 60th meeting of the American College of Cardiology; Apr 2011; New Orleans, USA.
26. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-2177.
27. Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thrombopro-phylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6): 513-523.
28. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10(5):807-814.
29. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
30. EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, et al. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med. 2012;366(14):1287-1297.
31. Botticelli Investigators, Writing Committe, Buller H, Deitchman D, Prins M, Segers A. Effcacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6(8):1313-1318.
32. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
33. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708.
34. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352.
35. Schulman S, Kakkar AK, Schellong SM, et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II); 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego.
36. Gerotziafas GT, Baccouche H, Sassi M, et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res. 2012;129(1):101-103.
37. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49(5):761-772.
38. Gerotziafas GT, Galea V, Mbemba E, et al. Tissue factor over- expression by human pancreatic cancer cells BXPC3 is related to higher prothrom-botic potential as compared to breast cancer cells MCF7. Thromb Res. 2012;129(6):779-786.
39. Borsig L. Antimetastatic activities of heparins and modifed heparins. Experimental evidence. Thromb Res. 2010;125 Suppl 2:S66-S71.
40. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009;102(2):258-267.
41. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost. 2007;33(7):688-694.